Design of a clinical trial using generalized pairwise comparisons to test a less intensive treatment regimen

Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia

(2022) Uday P. Kulkarni et al.   Blood Cancer Journal

Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial)

(2021) Li Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Net Benefit of a treatment should take the correlation between benefits and harms into account

(2021) Marc Buyse et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial

(2018) Hong-Hu Zhu et al.   LANCET ONCOLOGY

Do non-inferiority trials of reduced intensity therapies show reduced effects? A descriptive analysis

(2018) Scott K Aberegg et al.   BMJ Open

Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631

(2017) Matthew A. Kutny et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

(2017) Uwe Platzbecker et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?

(2017) Everardo D Saad et al.   JNCI-Journal of the National Cancer Institute

Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?

(2017) Everardo D Saad et al.   JNCI-Journal of the National Cancer Institute

Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab

(2016) Yasmin Abaza et al.   BLOOD

The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials

(2016) Julien Péron et al.   JAMA Oncology

Large sample inference for a win ratio analysis of a composite outcome based on prioritized components: Table 1.

(2015) Ionut Bebu et al.   BIOSTATISTICS

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

(2015) Alan K Burnett et al.   LANCET ONCOLOGY

Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy

(2014) Steven E. Coutre et al.   BRITISH JOURNAL OF HAEMATOLOGY

Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia

(2013) Francesco Lo-Coco et al.   NEW ENGLAND JOURNAL OF MEDICINE

Non-inferiority trials in breast and non-small cell lung cancer: Choice of non-inferiority margins and other statistical aspects

(2012) Everardo D. Saad et al.   ACTA ONCOLOGICA

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

(2012) H. J. Iland et al.   BLOOD

Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial

(2012) A K Burnett et al.   LEUKEMIA

Through the looking glass: understanding non-inferiority

(2011) Jennifer Schumi et al.   Trials

Potential pitfalls in the design and reporting of clinical trials

(2010) Matthew R Sydes et al.   LANCET ONCOLOGY

Room for Improvement in Conducting and Reporting Non-Inferiority Randomized Controlled Trials on Drugs: A Systematic Review

(2010) Grace Wangge et al.   PLoS One

Generalized pairwise comparisons of prioritized outcomes in the two-sample problem

(2010) Marc Buyse   STATISTICS IN MEDICINE

Current issues in non-inferiority trials

(2007) Thomas R. Fleming   STATISTICS IN MEDICINE